Clinical implication of urinary midkine as a sensitive biomarker of acute kidney injury

尿中期因子作为急性肾损伤敏感生物标志物的临床意义

基本信息

  • 批准号:
    18390247
  • 负责人:
  • 金额:
    $ 10.57万
  • 依托单位:
  • 依托单位国家:
    日本
  • 项目类别:
    Grant-in-Aid for Scientific Research (B)
  • 财政年份:
    2006
  • 资助国家:
    日本
  • 起止时间:
    2006 至 2007
  • 项目状态:
    已结题

项目摘要

Although acute kidney injury (AKI) is the most important predictor of the prognosis of the patients treated in the field of ICU, there have been no sensitive biomarkers to diagnose AKI before the rising of serum creatinine. Recently, several urinary biomarkers such as NGAL, IL-18, KIM-1, NHE3, KC, and L-FABP are reported as a candidate of new sensitive biomarker of AKI.We reported that midkine(MK), a heparin-binding growth factor, was induced in the diseased kidneys and promoted chemotaxis of leukocytes in the animal models of an ischemic renal reperfusion injury(Sato W., et. al., J Immunol 2001 ; 167 : 3463-3469). The enhanced expression of MK was detected mainly in the proximal tubules after ischemic injuries. Here, we evaluated whether human MK is shed into urine from the tubular epithelial cells, and may serve as a potent urinary biomarker of acute kidney injuries in human.Western blot analysis showed that the increased expression of MK was detected in the culture media from cultur … More ed human tubular epithelial(HK2)cells treated with hypoxia, but not from HK2 cells treated with 20 μM BSA. There were no differences in the MK expression in the cell lysates.For the measurement of urinary MK, 583 patients, including controls (n=33), patients with different forms of acute tubular necrosis (ATN) (n=33), and patients with other chronic renal diseases(n= 517), were studied. Urinary MK level was determined by enzyme-linked immunoassay.The urinary MK levels were significantly higher in patients with ATN compared to levels in patients with other chronic renal diseases or controls. For concentration in urine of MK, the receiver-operating characteristic(ROC)curve analysis for diagnosis of ATN showed that sensitivity was 97.0 %, and specificity was 91.1 % for a cut-off value of 70.0 pg/ml.We have confirmed that urinary MK level serves as a sensitive biomarker of ATN facilitating the early diagnosis of the disease. We obtained the patent(2008-048954, Ref : K20070222)for "Clinical examination for the early diagnosis of AKI : Urinary MK measurement". Less
急性肾损伤(acute kidney injury,阿基)是重症监护病房(ICU)中最重要的预后指标,但在血肌酐升高之前,尚无敏感的生物标志物诊断阿基。最近,NGAL、IL-18、KIM-1、NHE 3、KC和L-FABP等几种尿液生物标志物被报道为阿基新的敏感生物标志物的候选者。我们报道了中间因子(MK),一种肝素结合生长因子,在缺血性肾再灌注损伤动物模型中,在患病肾脏中被诱导并促进白细胞的趋化性(Sato W.,et.例如,J Immunol 2001 ; 167:3463-3469)。缺血损伤后MK表达增强主要在近端肾小管。在此,我们评估了人MK是否从肾小管上皮细胞脱落到尿液中,并可能作为人类急性肾损伤的有效尿液生物标志物。Western印迹分析显示,在培养的肾小管上皮细胞的培养基中检测到MK的表达增加。 ...更多信息 艾德对缺氧处理的人肾小管上皮细胞(HK 2)进行了诱导,但对20 μM BSA处理的HK 2细胞未进行诱导。尿MK测定包括正常对照组(n=33)、急性肾小管坏死(ATN)组(n = 33)和其他慢性肾脏疾病组(n= 517)共583例患者。采用酶联免疫法测定尿MK水平,ATN患者尿MK水平显著高于其他慢性肾脏疾病患者和对照组。尿MK浓度诊断ATN的受试者工作特征(ROC)曲线分析显示,以70.0 pg/ml为界值,敏感性为97.0%,特异性为91.1%,提示尿MK水平可作为ATN的敏感生物标志物,有助于ATN的早期诊断。我们获得了专利(2008-048954,参考号:K20070222)“用于阿基早期诊断的临床检查:尿MK测量”。少

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
A protein toxin from the sea anemone Phyllodiscus semoni targets the kidney and causes a severe renal injury with predominant glomerular endothelial damage
  • DOI:
    10.2353/ajpath.2007.060984
  • 发表时间:
    2007-08-01
  • 期刊:
  • 影响因子:
    6
  • 作者:
    Mizuno, Masashi;Nozaki, Masatoshi;Matsuo, Seiichi
  • 通讯作者:
    Matsuo, Seiichi
Effects of olprinone, a phosphodiesterase III inhibitor, on ischemic acute renal failure
  • DOI:
    10.1111/j.1442-2042.2007.01689.x
  • 发表时间:
    2007-03-01
  • 期刊:
  • 影响因子:
    2.6
  • 作者:
    Anas, Chabouk;Ozaki, Takenori;Matsuo, Seiichi
  • 通讯作者:
    Matsuo, Seiichi
High levels of complement C3a receptor in the glomeruli in lupus nephritis
  • DOI:
    10.1053/j.ajkd.2007.02.271
  • 发表时间:
    2007-05-01
  • 期刊:
  • 影响因子:
    13.2
  • 作者:
    Mizuno, Masashi;Blanchin, Stephanie;Matsuo, Seiichi
  • 通讯作者:
    Matsuo, Seiichi
Adipose Derived Stromal Cells Cultured in Low-Serum Media Secrete High Levels of Cytokines and Ameliorate Acute Kidney Injury
在低血清培养基中培养的脂肪源性基质细胞分泌高水平的细胞因子并改善急性肾损伤
  • DOI:
  • 发表时间:
    2007
  • 期刊:
  • 影响因子:
    0
  • 作者:
    Takenori Ozaki;Shoichi Maruyama;Tatsuto Watanabe;Shigejiro Iwashima;Kaoru Yasuda;Tokunori Yamamoto;Yasuo Kitagawa;Momokazu Gotoh;Yukio Yuzawa;Seiichi Matsuo
  • 通讯作者:
    Seiichi Matsuo
Midkine is involved in tubulointerstitial inflammation associated with diabetic nenhronathy
中期因子参与与糖尿病肾病相关的肾小管间质炎症
  • DOI:
  • 发表时间:
    2007
  • 期刊:
  • 影响因子:
    0
  • 作者:
    Kosugi;T
  • 通讯作者:
    T
{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

MATSUO Seiichi其他文献

MATSUO Seiichi的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('MATSUO Seiichi', 18)}}的其他基金

Development of novel therapy for kidney injury by leukocyte targeting antibody-fused Bionanocapsules
开发白细胞靶向抗体融合生物纳米胶囊治疗肾损伤的新疗法
  • 批准号:
    25670408
  • 财政年份:
    2013
  • 资助金额:
    $ 10.57万
  • 项目类别:
    Grant-in-Aid for Challenging Exploratory Research
Elucidation of molecular mechanisms involved in the immunomodulatory function of newly developed adipose tissue derived mesenchymal stem cells
阐明新开发的脂肪组织来源的间充质干细胞的免疫调节功能的分子机制
  • 批准号:
    23659443
  • 财政年份:
    2011
  • 资助金额:
    $ 10.57万
  • 项目类别:
    Grant-in-Aid for Challenging Exploratory Research
International comparison of genomic variations for prognostic factors in chronic kidney disease
慢性肾脏病预后因素基因组变异的国际比较
  • 批准号:
    23406027
  • 财政年份:
    2011
  • 资助金额:
    $ 10.57万
  • 项目类别:
    Grant-in-Aid for Scientific Research (B)
Epidemiological analysis on chronic kidney disease in Asian population after standardization of creatinine measurement
肌酐测量标准化后亚洲人群慢性肾脏病的流行病学分析
  • 批准号:
    20406022
  • 财政年份:
    2008
  • 资助金额:
    $ 10.57万
  • 项目类别:
    Grant-in-Aid for Scientific Research (B)
Asian Collaborative Study for Creation of GFR Estimation Equation (ACOS-CG-FREE)
创建 GFR 估计方程的亚洲合作研究 (ACOS-CG-FREE)
  • 批准号:
    18406032
  • 财政年份:
    2006
  • 资助金额:
    $ 10.57万
  • 项目类别:
    Grant-in-Aid for Scientific Research (B)
Basic research for the development of new therapeutic measures against progressive tubuloinetsrtitial injury.
开发针对进行性肾小管损伤的新治疗措施的基础研究。
  • 批准号:
    15390269
  • 财政年份:
    2003
  • 资助金额:
    $ 10.57万
  • 项目类别:
    Grant-in-Aid for Scientific Research (B)
Research on The Role of Proximal Tubular Cells in The Development of Tubulointerstitinal Injury.
近端肾小管细胞在肾小管间质损伤发展中作用的研究。
  • 批准号:
    13671110
  • 财政年份:
    2001
  • 资助金额:
    $ 10.57万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Development of a novel therapeutic approach to the renal injury by the control of anaphylatoxins.
通过控制过敏毒素开发一种新的肾损伤治疗方法。
  • 批准号:
    13557085
  • 财政年份:
    2001
  • 资助金额:
    $ 10.57万
  • 项目类别:
    Grant-in-Aid for Scientific Research (B)
The Role of Anaphylatoxins, C3a, C5a, in Renal Injury.
过敏毒素、C3a、C5a 在肾损伤中的作用。
  • 批准号:
    11671033
  • 财政年份:
    1999
  • 资助金额:
    $ 10.57万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Research on The Mechanisms of Tubulointerstitial Injury by Proteinuria.
蛋白尿损伤肾小管间质的机制研究。
  • 批准号:
    09671160
  • 财政年份:
    1997
  • 资助金额:
    $ 10.57万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)

相似国自然基金

基于DNA甲基化交互网络的癌症hallmark挖掘及其在癌症转移biomarker筛选中的应用
  • 批准号:
    61602201
  • 批准年份:
    2016
  • 资助金额:
    20.0 万元
  • 项目类别:
    青年科学基金项目
血清miRNAs成为一种新的biomarker在PD诊断中的价值和LRRK2基因调控的机制研究
  • 批准号:
    81170309
  • 批准年份:
    2011
  • 资助金额:
    50.0 万元
  • 项目类别:
    面上项目
非小细胞肺癌Biomarker的Imaging MS研究新方法
  • 批准号:
    30672394
  • 批准年份:
    2006
  • 资助金额:
    30.0 万元
  • 项目类别:
    面上项目

相似海外基金

酸化ストレス応答アポトーシス誘導蛋白のUCに対する新規Biomarker探索と治療への展開
寻找治疗 UC 的氧化应激反应性凋亡诱导蛋白的新生物标志物并开发治疗方法
  • 批准号:
    24K11919
  • 财政年份:
    2024
  • 资助金额:
    $ 10.57万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
肝内胆管癌新規Biomarkerの同定及び癌周囲間質を標的とした新規治療開発
鉴定肝内胆管癌的新型生物标志物并开发针对癌周基质的新疗法
  • 批准号:
    24K19350
  • 财政年份:
    2024
  • 资助金额:
    $ 10.57万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
収縮能が保たれた心不全の機械学習分類とmicroRNAなどのbiomarkerの探索
机器学习对具有保留收缩性的心力衰竭进行分类并搜索 microRNA 等生物标志物
  • 批准号:
    24K19007
  • 财政年份:
    2024
  • 资助金额:
    $ 10.57万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Development of a predictive biomarker for Parkinson's disease
帕金森病预测生物标志物的开发
  • 批准号:
    MR/Y019415/1
  • 财政年份:
    2024
  • 资助金额:
    $ 10.57万
  • 项目类别:
    Research Grant
Sleep and circadian dysfunction in ageing and neurodegeneration: a life course and biomarker study of the British 1946 birth cohort.
衰老和神经退行性疾病中的睡眠和昼夜节律功能障碍:对英国 1946 年出生队列的生命历程和生物标志物研究。
  • 批准号:
    MR/Y009452/1
  • 财政年份:
    2024
  • 资助金额:
    $ 10.57万
  • 项目类别:
    Fellowship
Biomarker-Based Platform for Early Diagnosis of Chronic Liver Disease to Enable Personalized Therapy (LIVERAIM)
基于生物标志物的慢性肝病早期诊断平台,以实现个性化治疗(LIVERAIM)
  • 批准号:
    10087822
  • 财政年份:
    2024
  • 资助金额:
    $ 10.57万
  • 项目类别:
    EU-Funded
Enhanced stratification of COPD patients via integration of a digitally enabled biomarker Point-of-Care test within a Remote Patient Monitoring tool
通过在远程患者监测工具中集成数字化生物标志物即时检测,增强 COPD 患者的分层
  • 批准号:
    10098600
  • 财政年份:
    2024
  • 资助金额:
    $ 10.57万
  • 项目类别:
    Collaborative R&D
QuBIE: Quantitative Biomarker Identification for Non-Endoscopic Prediction and Monitoring of Treatment Response in Eosinophilic Oesophagitis
QuBIE:用于非内镜预测和监测嗜酸性食管炎治疗反应的定量生物标志物鉴定
  • 批准号:
    10083253
  • 财政年份:
    2024
  • 资助金额:
    $ 10.57万
  • 项目类别:
    Collaborative R&D
膵癌腫瘍内線維化に着目した術前化学療法効果予測に関する画像biomarkerの確立
建立预测胰腺癌瘤内纤维化术前化疗效果的影像生物标志物
  • 批准号:
    24K18824
  • 财政年份:
    2024
  • 资助金额:
    $ 10.57万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
I-Corps: Developing A Blood-Based Biomarker for the Detection and Monitoring of Amyotrophic Lateral Sclerosis
I-Corps:开发一种基于血液的生物标志物,用于检测和监测肌萎缩侧索硬化症
  • 批准号:
    2317745
  • 财政年份:
    2023
  • 资助金额:
    $ 10.57万
  • 项目类别:
    Standard Grant
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了